Next Level Private LLC lifted its holdings in Pfizer Inc. (NYSE:PFE – Free Report) by 13.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 53,772 shares of the biopharmaceutical company’s stock after purchasing an additional 6,214 shares during the quarter. Next Level Private LLC’s holdings in Pfizer were worth $1,548,000 as of its most recent SEC filing.
A number of other institutional investors have also made changes to their positions in PFE. Fulton Bank N.A. raised its position in Pfizer by 4.7% during the third quarter. Fulton Bank N.A. now owns 176,239 shares of the biopharmaceutical company’s stock worth $5,846,000 after acquiring an additional 7,991 shares in the last quarter. Portside Wealth Group LLC bought a new position in shares of Pfizer in the second quarter valued at about $2,072,000. Adage Capital Partners GP L.L.C. raised its position in shares of Pfizer by 40.5% in the third quarter. Adage Capital Partners GP L.L.C. now owns 4,739,672 shares of the biopharmaceutical company’s stock valued at $157,215,000 after purchasing an additional 1,365,295 shares during the period. Brookstone Capital Management raised its position in shares of Pfizer by 88.5% in the third quarter. Brookstone Capital Management now owns 452,352 shares of the biopharmaceutical company’s stock valued at $14,109,000 after purchasing an additional 212,369 shares during the period. Finally, ETF Store Inc. raised its position in shares of Pfizer by 12.0% in the third quarter. ETF Store Inc. now owns 6,803 shares of the biopharmaceutical company’s stock valued at $214,000 after purchasing an additional 727 shares during the period. Institutional investors own 68.36% of the company’s stock.
Pfizer Trading Up 0.7 %
Shares of Pfizer stock opened at $27.78 on Thursday. The firm’s 50 day moving average is $27.47 and its 200 day moving average is $29.47. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69. Pfizer Inc. has a 1 year low of $25.61 and a 1 year high of $42.22. The firm has a market capitalization of $157.31 billion, a PE ratio of 77.14, a price-to-earnings-growth ratio of 1.24 and a beta of 0.61.
Wall Street Analysts Forecast Growth
Several equities analysts have recently weighed in on the stock. Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. UBS Group decreased their price target on shares of Pfizer from $34.00 to $27.00 and set a “neutral” rating on the stock in a research note on Thursday, December 14th. TD Cowen downgraded shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target on the stock. in a research note on Thursday, January 4th. Barclays decreased their price target on shares of Pfizer from $34.00 to $28.00 and set an “equal weight” rating on the stock in a research note on Thursday, December 14th. Finally, Truist Financial decreased their price target on shares of Pfizer from $42.00 to $36.00 and set a “buy” rating on the stock in a research note on Thursday, December 14th. Twelve analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $36.88.
View Our Latest Research Report on PFE
Pfizer Profile
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
See Also
- Five stocks we like better than Pfizer
- Short Selling: How to Short a Stock
- Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
- What is MarketRank™? How to Use it
- Delta Airline’s Put Option Activity Isn’t Bad News
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Krispy Kreme’s Sweet Deal: McDonald’s Partnership Sparks Growth?
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.